Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in the circulation after sumatriptan

Jakob Møller Hansen; Jan Fahrenkrug; Jesper Troensegaard Petersen; Troels Wienecke; Karsten Skovgaard Olsen; Messoud Ashina

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in the circulation after sumatriptan

Jakob Møller Hansen, Jan Fahrenkrug, Jesper Troensegaard Petersen, Troels Wienecke, Karsten Skovgaard Olsen, Messoud Ashina

Department of Neurology

590 Downloads (Pure)

Abstract

The origin of migraine pain is still elusive, but increasingly researchers focus on the neuropeptides in the perivascular space of cranial vessels as important mediators of nociceptive input during migraine attacks. The parasympathetic neurotransmitters, pituitary adenylate cyclase activating peptide-38 (PACAP38) and vasoactive intestinal peptide (VIP) may be released from parasympathetic fibres and activate sensory nerve fibres during migraine attacks. Triptans are effective and well tolerated in acute migraine management but the exact mechanism of action is still debated. Triptans might reduce circulating neuropeptides. To examine this question, we examined the effect of sumatriptan on VIP and PACAP levels in vivo, under conditions without trigeminovascular system activation.

Original language	English
Journal	Scandinavian Journal of Pain
Volume	4
Issue number	4
Pages (from-to)	211
Number of pages	216
ISSN	1877-8860
Publication status	Published - 2013

Access to Document

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in the circulation after sumatriptanFinal published version, 477 KB

http://www.sciencedirect.com/science/article/pii/S1877886013000384

Cite this

@article{871071f87145454cb5988f503ad063c0,

title = "Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in the circulation after sumatriptan",

abstract = "The origin of migraine pain is still elusive, but increasingly researchers focus on the neuropeptides in the perivascular space of cranial vessels as important mediators of nociceptive input during migraine attacks. The parasympathetic neurotransmitters, pituitary adenylate cyclase activating peptide-38 (PACAP38) and vasoactive intestinal peptide (VIP) may be released from parasympathetic fibres and activate sensory nerve fibres during migraine attacks. Triptans are effective and well tolerated in acute migraine management but the exact mechanism of action is still debated. Triptans might reduce circulating neuropeptides. To examine this question, we examined the effect of sumatriptan on VIP and PACAP levels in vivo, under conditions without trigeminovascular system activation.",

author = "Hansen, \{Jakob M{\o}ller\} and Jan Fahrenkrug and Petersen, \{Jesper Troensegaard\} and Troels Wienecke and Olsen, \{Karsten Skovgaard\} and Messoud Ashina",

year = "2013",

language = "English",

volume = "4",

pages = "211",

journal = "Scandinavian Journal of Pain",

issn = "1877-8860",

publisher = "Walter de Gruyter GmbH",

number = "4",

}

TY - JOUR

T1 - Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in the circulation after sumatriptan

AU - Hansen, Jakob Møller

AU - Fahrenkrug, Jan

AU - Petersen, Jesper Troensegaard

AU - Wienecke, Troels

AU - Olsen, Karsten Skovgaard

AU - Ashina, Messoud

PY - 2013

Y1 - 2013

N2 - The origin of migraine pain is still elusive, but increasingly researchers focus on the neuropeptides in the perivascular space of cranial vessels as important mediators of nociceptive input during migraine attacks. The parasympathetic neurotransmitters, pituitary adenylate cyclase activating peptide-38 (PACAP38) and vasoactive intestinal peptide (VIP) may be released from parasympathetic fibres and activate sensory nerve fibres during migraine attacks. Triptans are effective and well tolerated in acute migraine management but the exact mechanism of action is still debated. Triptans might reduce circulating neuropeptides. To examine this question, we examined the effect of sumatriptan on VIP and PACAP levels in vivo, under conditions without trigeminovascular system activation.

AB - The origin of migraine pain is still elusive, but increasingly researchers focus on the neuropeptides in the perivascular space of cranial vessels as important mediators of nociceptive input during migraine attacks. The parasympathetic neurotransmitters, pituitary adenylate cyclase activating peptide-38 (PACAP38) and vasoactive intestinal peptide (VIP) may be released from parasympathetic fibres and activate sensory nerve fibres during migraine attacks. Triptans are effective and well tolerated in acute migraine management but the exact mechanism of action is still debated. Triptans might reduce circulating neuropeptides. To examine this question, we examined the effect of sumatriptan on VIP and PACAP levels in vivo, under conditions without trigeminovascular system activation.

M3 - Journal article

SN - 1877-8860

VL - 4

SP - 211

JO - Scandinavian Journal of Pain

JF - Scandinavian Journal of Pain

IS - 4

ER -

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in the circulation after sumatriptan

Abstract

Access to Document

Fingerprint

Cite this